Skip to Content

'
Xiao Ni, MD, PhD

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Dermatology - Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Adjunct Faculty, The University of Texas, Graduate School of Biomedical Sciences, Houston, TX

Bio Statement

Have leaded a preclinical study about dendritic cell vaccine on cutaneous T-cell lymphoma (CTCL). By finishing this project, we established the optimal protocol for further clinical study, and we also established a collaborative team of basic immunologists, physician scientists, and clinicians.

Have three ongoing research projects:

One project is implementing to the clinical trial of anti-CCR4 antibody on CTCL. We are assessing the effect of this antibody on regulatory T cells, an immune suppressive cell, if the antibody could reduce or eliminate the Treg, it could be used for many tumors which have increased Tregs.

Another project is to identify the biomarkers for response and resistance to photopheresis for CTCL, and hope that we could find a set of signature genes to help us subgroup patients for better specific therapy indications.

The new project is to find molecular genetic mutations contributing to CTCL and further determine the effect of tumor-associated molecular markers on overall survival, progression free survival and response to targeted therapy.

Research Interests

Skin immunology, tumor immunology, immunotherapy, dendritic cell subsets, and T cell subsets

Education & Training

Degree-Granting Education

1999 Peking Union Medical College, Beijing, China, PHD, Investigative Dermatology
1983 Nantong Medical College, Nantong, China, MD, Medicine

Postgraduate Training

2/2000-12/2003 Postdoctoral Fellow, Tumor immunology, Immunotherapy, Cutaneous T-cell Lymphoma, The University of Texas MD Anderson Cancer Center, Houston, TX
1988-1989 Clinical Fellowship, Dermatopathology, Institution of Dermatology, The Chinese Academy of Medicine and Sciences, Nanjing, China
1984-1988 Clinical Residency, Dermatology, University of Nanjing - Affiliated Gulou Hospital, Nanjing, Jiangsu, China

Experience/Service

Academic Appointments

Assistant Professor, Department of Dermatology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2008-8/2014

Institutional Committee Activities

Member, The Clinical Research Committee, 9/2008-8/2010
Research mentor, Co-advisor, The University of Texas Graduate School of Biomedical Sciences - Advisory/Supervisory Committee, 3/2007-12/2012

Honors and Awards

2008 Young Investigator Award, Cutaneous Lymphoma Foundation
2007 Semi-Finalist, Division of Internal Medicine Research Retreat
2005 Research Grant Award, Ladies Leukemia League
2003 Research Grant Award, Dermatology Foundation
2002 Trainee Excellence Award, MD Anderson Alumni and Faculty Association
1998 Outstanding Young Investigator, The Institute of Dermatology, the Chinese Academy of Medicine and Sciences, China
1996 Graduate Student Excellence Award, The Chinese Academy of Medicine and Sciences, Peking Union Medial College, China
1994 Excellent Teacher, University of Nanjing - Affiliated Gulou Hospital, China
1993 Outstanding Employee, University of Nanjing - Affiliated Gulou Hospital, China

Professional Memberships

American Society of Hematology
Member, 2007-present
The American Association for the Advancement of Science
Member, 2002-present
The Society of Investigative Dermatology
Member, 2002-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Ni X, Jorgensen JL, Goswami M, Challagundla P, Decker WK, Kim YH, Duvic MA. Reduction of Regulatory T cells by Mogamulizumab, a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients with Aggressive/Refractory Mycosis Fungoides and Sézary Syndrome. Clin Cancer Res. e-Pub 11/2014. PMID: 25376389.
2. Shiue LH, Ni X, Prieto VG, Jorgensen JL, Curry JL, Goswami M, Sweeney SA, Duvic M. A case of invisible leukemic cutaneous T cell lymphoma with a regulatory T cell clone. Int J Dermatol 18(9):1365-4632, 9/2013. e-Pub 1/18/2012. PMID: 22257096.
3. Shiue LH, Alousi AM, Wei C, Hosing CM, Duvic M, Ni X. Augmentation of blood dendritic cells by extracorporeal photopheresis in patients with leukemic cutaneous T-cell lymphoma and graft-versus-host disease. J Invest Dermatol 133(8):2098-100., 8/2013. e-Pub 3/21/2013. PMID: 23519332.
4. Goswami M, Duvic M, Dougherty A, Ni X. Increased Twist expression in advanced stage of mycosis fungoides and Sézary syndrome. J Cutan Pathol 39(5):500-7, 5/2012. PMCID: PMC3796850.
5. Ni X, Richmond H, Liao X, Decker W, Shiue L, Shpall E, Duvic M.. Induction of T-cell Responses against Cutaneous T-cell Lymphomas ex vivo by Autologous Dendritic Cells Transfected with Amplified Tumor RNA. J Invest Dermatol 128(11):2631-2639, 11/2008. e-Pub 5/2008. PMID: 18480841.
6. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109(1):31-9, 1/1/2007. PMID: 16960145.
7. Doherty SD, Ni X, Doherty CB, Jones D, Zhao X, Owen LB, Duvic M. Abnormal expression of interleukin-23 in mycosis fungoides/Sézary syndrome lesions. Arch Dermatol Res 298(7):353-6, 12/2006. PMID: 17021762.
8. Zhang C, Richon V, Ni X, Talpur R, Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 125(5):1045-52, 11/2005. PMID: 16297208.
9. Ni X, Zhang C, Talpur R, Duvic M. Resistance to activation-induced cell death and bystander cytotoxicity via the Fas/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas. J Invest Dermatol 124(4):741-750, 2005. PMID: 15816832.
10. Zhang C, Ni X, Konopleva M, Andreeff M, Duvic M. The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides/Sézary syndrome cells. J Invest Dermatol 123(2):380-7, 8/2004. PMID: 15245439.
11. Apisarnthanarax N, Talpur R, Ward S, Ni X, Kim HW, Duvic M. Tazarotene 0.1% Gel for Refractory Mycosis Fungoides Lesions: An Open-label Pilot Study. J Am Acad Dermatol 50(5):600-607, 2004. PMID: 15034511.
12. Duvic M, Ni X, Talpur R, Herne K, Schulz C, Sui D, Ward S, Joseph A, Hazarika P. Tazarotene induced gene-3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application. J Invest Dermatol 121(4):902-9, 10/2003. PMID: 14632211.
13. Zhang CL, Hazarika P, Ni X, Weidner DA, Duvic M. Induction of Apoptosis by Bexarotene in Cutaneous T-Cell Lymphoma Cells: Relevance to Mechanism of therapeutic Action. Clin Cancer Res 8(5):1234-1240, 2002. PMID: 12006543.
14. Ni X, Hazarika P, Zhang C, Talpur R, Duvic M. Fas ligand expression by neoplastic T- lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape? . Clin Cancer Res 7(9):2682-92, 9/2001. PMID: 11555580.
15. Ni X, Sun JF. Methygreen-Pyronin staining for apoptotic cells in psoriatic lesions. Journal of Clinical Dermatology 29(6):334-336, 2000.
16. Ni X, Sun JF, Zeng XS,Sang HG, Li AM, Ye GY. The excessive proliferation and apoptosis are correlated with the abnormal expression of c-myc, P53 and bcl-2 in psoriatic lesions. Chinese Journal of Dermatology 33(4):240-242, 2000.
17. Ni X, Sun JF. The value of pathological examination in the diagnosis of atypical psoriasis. Chinese Journal of Dermatology and Venereology 13(2):75-76, 1999.
18. Ni X, Jiang YQ, Sun JF. Apoptosis and Pilomatricoma. Chinese Journal of Dermatology 31(6):386-387, 1998.
19. Ni X, Yang HP, Sun JF. Excessive proliferation and apoptosis in both keratinocytes and lymphocytic infiltrates of psoriatic lesions. Chinese Journal of Dermatology 31(2):95-96, 1998.
20. Yang HP, Ni X, Sun JF. Psoriasis arthropathica: analysis of 26 cases. Chinese Journal of Dermatology 31(2):114- 115, 1998.
21. Ni X. A case study: Piebaldism and the pedigree analysis. Journal of Clinical Dermatology 24(1):50, 1995.
22. Ni X, Chen ZG, Zhu WW. Epidermal-grafting for a patient with Piebaldism. Chinese Journal of Dermatology 28(4):261, 1995.
23. Ni X, Fang Y, Zhu WW. A clinical trial of Germanium Huangqi for psoriasis vulgaris. Chinese Journal of Dermatology 27(6):377-378, 1994.
24. Ni X, Lu ML, Li FQ. Chinese herbs for summer dermatitis. Journal of Clinical Dermatology 23(1):46, 1994.
25. Ni X. Two cases of anhidrotic ectodermal dysplasia. Chinese Journal of Dermatology 27(3):183, 1994.
26. Gu JG, Gu XJ, Ni X. Clinical efficacy of enoxacin for skin infections. Chinese Journal of Antibiotics 18(6):465-468, 1993.
27. Ni X, Li FQ. Non-papillomatous hyperplastic lesions in genitalia. Jiangsu Medical Journal 19:282, 1993.
28. Ni X, Li FQ. A case report: pseudo-acanthosis nigricans. Chinese Journal of Dermatology 25(5):348, 1992.
29. Ni X, Li FQ, Liu JH. A case report: cutaneous T-cell lymphoma manifesting lethal midline granuloma. Chinese Journal of Dermatology 24(4):275-276, 1991.
30. Shiue LH, Couturier J, Lewis D, Wei C, Duvic M, and Ni. Response to extracorporeal photopheresis in patients with leukemic cutaneous T cell lymphoma is associated with reduction in both malignant CD4+26- T cells and CD4+Foxp3+CD25- T cells. Photodermatology, Photoimmunology & Photomedicine. Submitted.

Invited Articles

1. Ni X, Duvic M. Dendritic cells and Cutaneous T-cell Lymphomas. G Ital Dermatol Venereol 146(2):103-13, 4/2011. PMID: 21505396.
2. Ni X, Sun JF. In situ polymerase chain reaction and its applications in the dermatology. Foreign Medical Sciences 23(5):279-282, 1997.
3. Ni X, Sun JF. The aberrant molecular biological pathways in the pathogenesis of psoriasis. Foreign Medical Sciences 23(2):85-87, 1997.

Book Chapters

1. Ni X. Dermatopathology - Introduction. In: The Basis of Modern Dermatology. The People's Medical Publishing House, 1035-1063, 2001.
2. Ni X, Sun J, Liu J. Dermatopathology in China. In: Chinese Modern Scientific Encyclopedia. Scientific Publishing House, 2000.
3. Ni X. Benign and Malignant epidermal tumors. In: Atlas of Dermatology and Venereology. The People's Medical Publishing House, 337-354, 1998.

Grant & Contract Support

Title: The Effect of ECP on Th1/Th2/Th17/Treg Cytokines and Related Molecules in Cutaneous T-Cell Lymphoma
Funding Source: American Skin Association
Role: Research Mentor
Duration: 1/1/2014 - 12/31/2014
 
Title: Molecular targets in Cutaneous T-cell lymphoma (CTCL)
Funding Source: Drs. Martin and Dorothy Spatz Foundation
Role: Co-Investigator
Principal Investigator: Madeleine Duvic
Duration: 11/1/2012 - 10/30/2015
 
Title: Identifying biomarkers of response and resistance to ECP in patients with MF/SS
Funding Source: Therakos, Inc.
Role: Principal Investigator
Duration: 11/1/2010 - 4/30/2015
 
Title: Effect of anti-CC chemokine receptor 4 (CCR4) monoclonal antibody on regulatory T cells and natural killer cells in patients with aggressive/refractory cutaneous T-cell lymphoma
Funding Source: Kyowa Hakko Kirin Co.LTD.
Role: Principal Investigator
Duration: 3/24/2009 - 9/30/2012
 
Title: Induction of Polyclonal T-cell Responses against Cutaneous T-cell Lymphomas by Autologous Dendritic Cells Transfected with Amplified Tumor RNA
Funding Source: Ladies Leukemia League
Role: Principal Investigator
Duration: 6/1/2005 - 5/31/2007
 
Title: Strategies for effective ex vivo priming of cutaneous T-cell lymphoma -specific cytotoxic T lymphocytes by autologous dendritic cells pulsed with whole tumor cells
Funding Source: Dermatology Foundation
Role: Principal Investigator
Duration: 8/1/2003 - 7/31/2005

Last updated: 11/19/2014